VistaGen Therapeutics Earnings Estimate
| VTGN Stock | USD 0.51 0.04 7.27% |
VistaGen Therapeutics Earnings per Share Projection vs Actual
About VistaGen Therapeutics Earnings Estimate
The earnings estimate module is a useful tool to check what professional financial analysts are assuming about the future of VistaGen Therapeutics earnings. We show available consensus EPS estimates for the upcoming years and quarters. Investors can also examine how these consensus opinions have evolved historically. We show current VistaGen Therapeutics estimates, future projections, as well as estimates 1, 2, and three years ago. Investors can search for a specific entity to conduct investment planning and build diversified portfolios. Please note, earnings estimates provided by Macroaxis are the average expectations of expert analysts that we track. If a given stock such as VistaGen Therapeutics fails to match professional earnings estimates, it usually performs purely. Wall Street refers to that as a 'negative surprise.' If a company 'beats' future estimates, it's usually called an 'upside surprise.'
Please read more on our stock advisor page.| Last Reported | Projected for Next Year | ||
| Retained Earnings | -468.8 M | -492.2 M | |
| Retained Earnings Total Equity | -240.8 M | -228.8 M | |
| Price Earnings Ratio | -3.2 K | -3 K | |
| Price Earnings To Growth Ratio | 53.85 | 56.54 |
Pair Trading with VistaGen Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if VistaGen Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in VistaGen Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving against VistaGen Stock
| 0.81 | DRTS | Alpha Tau Medical | PairCorr |
| 0.74 | EQ | Equillium | PairCorr |
| 0.69 | GXEA | Galapagos NV Earnings Call Next Week | PairCorr |
| 0.68 | VERA | Vera Therapeutics Sell-off Trend | PairCorr |
| 0.64 | 6C1 | CytomX Therapeutics | PairCorr |
The ability to find closely correlated positions to VistaGen Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace VistaGen Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back VistaGen Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling VistaGen Therapeutics to buy it.
The correlation of VistaGen Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as VistaGen Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if VistaGen Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for VistaGen Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out World Market Map to better understand how to build diversified portfolios, which includes a position in VistaGen Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in census. To learn how to invest in VistaGen Stock, please use our How to Invest in VistaGen Therapeutics guide.You can also try the Idea Breakdown module to analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes.
Will Biotechnology sector continue expanding? Could VistaGen diversify its offerings? Factors like these will boost the valuation of VistaGen Therapeutics. If investors know VistaGen will grow in the future, the company's valuation will be higher. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every VistaGen Therapeutics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (1.92) | Revenue Per Share | Quarterly Revenue Growth 0.41 | Return On Assets | Return On Equity |
Investors evaluate VistaGen Therapeutics using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating VistaGen Therapeutics' intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. External factors like market trends, sector rotation, and investor psychology can cause VistaGen Therapeutics' market price to deviate significantly from intrinsic value.
Please note, there is a significant difference between VistaGen Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if VistaGen Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. Conversely, VistaGen Therapeutics' market price signifies the transaction level at which participants voluntarily complete trades.